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Polymer micelles are promising drug delivery vehicles for the delivery of anticancer agents to tumors. Often, anticancer drugs
display potent cytotoxic eﬀects towards cancer cells but are too hydrophobic to be administered in the clinic as a free drug. To
address this problem, a polymer micelle was designed using a triblock copolymer (ITP-101) that enables hydrophobic drugs to be
encapsulated. An SN-38 encapsulated micelle, IT-141, was prepared that exhibited potent in vitro cytotoxicity against a wide array
of cancer cell lines. In a mouse model, pharmacokinetic analysis revealed that IT-141 had a much longer circulation time, plasma
exposure, and tumor exposure compared to irinotecan. IT-141 was also superior to irinotecan in terms of antitumor activity,
exhibiting greater tumor inhibition in HT-29 and HCT116 colorectal cancer xenograft models at half the dose of irinotecan.
The antitumor eﬀect of IT-141 was dose-dependent and caused complete growth inhibition and tumor regression at well-
tolerated doses. Varying the speciﬁc concentration of SN-38 within the IT-141 micelle had no detectible eﬀect on this antitumor
activity, indicating no diﬀerences in activity between diﬀerent IT-141 formulations. In summary, IT-141 is a potent micelle-based
chemotherapy that holds promise for the treatment of colorectal cancer.
1.Introduction
It was estimated that there were 1,500,000 new cancer cases
and approximately 560,000 deaths out of cancer in 2009
[1]. Chemotherapy is an important treatment option for
patients with cancer, however chemotherapy drugs suﬀer
from numerous problems including nonspeciﬁc uptake by
healthy tissue, poor circulation times, and suboptimal accu-
mulation in the tumor. Often, a large percentage of cytotoxic
drug administered to the patient does not reach the tumor
environment, but rather is distributed throughout the body,
resulting in the many toxic eﬀects associated with chemo-
therapy and a narrowing of the drug’s therapeutic window.
The delivery of chemotherapeutic drugs to tumors is still a
major hurdle in the eradication of cancer, and the continual
development of drug delivery technologies is vital to future
breakthroughs in chemotherapy. Polymer micelles oﬀer a
promising approach to achieving these goals due to their
inherent ability to overcome multiple biological barriers,
such as avoidance of the reticuloendothelial system (RES)
[2]. Due to their unique size range (20–150nm), micelles
are able to avoid renal clearance (typically less than 20nm)
and uptake by the liver and spleen (particles greater than
150nm). These micelles can also preferentially accumulate
in solid tumors via the enhanced permeation and retention
(EPR) eﬀect [3, 4]. The EPR eﬀect is a consequence of the
disorganized nature of the tumor vasculature, which results
in increased permeability of polymer therapeutics and drug
retention at the tumor site. Due to these promising aspects,
a number of groups have developed various polymer micelle
motifs, encapsulating a wide range of therapeutic classes [5–
17].
Colon cancer is the third most common cancer in men
and women in most of the developed world [1]. Irinotecan,
a topoisomerase I inhibitor, is approved in the clinic for
colorectal cancer ﬁrst-line therapy in combination with 5-
ﬂuorouracil/leucovorin/oxaliplatin (FOLFOX) regimen or
for monotherapy in second-line therapy following a failed
FOLFOX regimen [18]. SN-38, the active metabolite of
irinotecan, is about 500–1000 times more cytotoxic than2 Journal of Drug Delivery
irinotecan [18–20]. Although irinotecan has demonstrated
clinical utility, it is highly ineﬃcient in delivering active SN-
38 to tumor tissue. Studies in humans have shown that
only three to four percent of the administered irinotecan
is actually converted to SN-38, which is reliant upon
activating carboxylesterase enzymes localized in the liver and
gastrointestinal tract [21]. In addition, up to 95% of SN-
38 is bound to circulating proteins such as albumin, which
drastically reduces its bioavailability [22]. Irinotecan treat-
ment also is accompanied by dose-limiting toxicities of grade
3 and 4 diarrhea and neutropenia [23]. These limitations
of irinotecan result in poor exposure of SN-38 to the tumor
environment and severe side eﬀects in the patient.
Becauseofitspotency,SN-38isanattractivemoleculefor
anticancer drug development. A major limitation, however,
offreeSN-38isthatitishydrophobicandisunabletobeused
as a free drug in the clinic. Several groups have addressed the
solubility problem of SN-38 by covalently attaching SN-38
to a polymer or peptide [24–26]. In particular, a polymeric
micellar formulation of SN-38 based on PEO-poly (glutamic
acid)blockcopolymersthroughchemicalconjugationofSN-
38 to the free carboxyl groups present on the poly (glutamic
acid) backbone has been developed [26]. This formulation,
known as NK012, as well as a peglyated SN-38 formulation
(EZN-2208), is currently in clinical trials [27, 28]. While
polymer-drug conjugates eﬀectively address solubility of
hydrophobic drugs, this prodrug approach is dependent on
enzymatic or chemical cleavage of the bond to release the
active drug. To develop an encapsulated formulation of SN-
38, SN-38 was loaded into a polymer micelle, resulting in
aqueous solubility of SN-38 without modiﬁcation of the
drug. This polymer micelle (termed IT-141) was evaluated
for pharmacokinetics and antitumor activity compared to
irinotecan. The data reported herein support IT-141 as a
promising new antineoplastic agent for the treatment of
colorectal cancer.
2.MaterialsandMethods
2.1. ITP-101 Synthesis. Azido-Poly(ethylene glycol)-t-butyl
carbonate-amine (N3-PEG-NH-BOC) was prepared as de-
scribed previously [29]. N-carboxy anhydrides (NCAs) were
prepared according to previously published procedures [30,
31]. N3-PEG12k-NH-Boc (150g, 12.5mmol) was dissolved
into 1L of CH2Cl2/diﬂuoracetic acid (DFA) (70/30) and was
allowed to stir at room temperature overnight. The product
was precipitated twice in diethyl ether and was recovered as
a white powder (Yield ∼90%): 1HN M R( d 6-DMSO) 7.77
(3H), 5.97 (1H), 3.83–3.21 (1050 H), 2.98 (2H) ppm.
N3-PEG10k-NH3/DFA (95g, 7.92mmol) was weighed
into an oven-dried, 2L-round-bottom ﬂask and was left
under vacuum for three hours before adding the NCA.
Asp(OBu) NCA (17.04g, 79.2mmol) was added to the
ﬂask; the ﬂask was evacuated under reduced pressure, and
subsequentlybackﬁlled withnitrogen gas.Dry N-methylpyr-
rolidone (NMP) (560mL) was introduced by cannula, and
the solution was heated to 60◦C. The reaction mixture was
allowed to stir for 24 hours at 60◦C under nitrogen gas.
Then, D-Leu NCA (24.88g, 158mmol) and Tyr (OBzl) NCA
(47.08g, 158mmol) were dissolved under nitrogen gas into
360mL of NMP into an oven-dried, round bottom ﬂask, and
the mixture was subsequently added to the polymerization
reaction via a syringe. The solution was allowed to stir at
60◦C for another three days at which point the reaction was
complete (as determined by HPLC). The solution was cooled
to room temperature, and diisopropylethylamine (DIPEA)
(10mL), dimethylaminopyridine (DMAP) (100mg), and
acetic anhydride (10mL) were added. Stirring was continued
for 1 hour at room temperature. The polymer was precip-
itated into diethyl ether (10L) and isolated by ﬁltration.
The solid was redissolved in dichloromethane (500mL)
and precipitated into diethyl ether (10L). The product was
isolated by ﬁltration and dried in vacuo to give the block
copolymer as an oﬀ-white powder (134.6g, Yield = 73%):
1HN M R( d 6-DMSO) δ 8.43–7.62 (50H), 7.35 (100H), 7.1
(40H), 6.82 (40H), 4.96 (40H), 4.63–3.99 (50H), 3.74–3.2
(1500H), 3.06–2.6 (60H), 1.36 (90H), 1.27–0.47 (180).
N3-PEG12K-b-Poly(Asp(OBu)10)-b-Poly(Tyr(OBzl)20-
co-D-Leu20)-Ac (134.6g, 6.4mmol) was dissolved into
1000mL of a solution of pentamethylbenzene (PMB, 0.5M)
in triﬂuoroacetic acid (TFA). The reaction was allowed
to stir for ﬁve hours at room temperature. The solution
was precipitated into a 10-fold excess of diethyl ether,
and the solid was recovered by ﬁltration. The polymer was
redissolvedinto800mLofdichloromethaneandprecipitated
into diethyl ether. An oﬀ-white polymer was obtained after
dryingtheproductovernightinvacuo(111.8g,Yield =93%):
1H NMR (d6-DMSO) δ 12.2 (10H), 9.1 (10H), 8.51–7.71
(50H), 6.96 (40H), 6.59 (40H), 4.69–3.96 (60H), 3.81–3.25
(1500H), 3.06–2.65 (60H), 1.0–0.43 (180). 1HN M R( d 6-
DMSO) δ 171.9, 171, 170.5, 170.3, 155.9, 130.6, 129.6, 127.9
115.3, 114.3, 70.7, 69.8, 54.5, 51.5, 50, 49.8, 49.4, 36.9, 36,
24.3, 23.3, 22.3, 21.2. IR (ATR) 3290, 2882, 1733, 1658, 1342,
1102, 962cm−1.
2.2. IT-141 Formulation. SN-38-loaded micelles were pre-
pared by dissolving 1g of ITP-101 in 200mL of water and
100mg of SN-38 in 8mL of methanol and 16mL of toluene.
The water was mixed with a Silverson LT4R shear mixer
at 10,000rpm at 4◦C, and the organic solution was added
dropwise. The solution was mixed for 30 minutes, then the
resulting emulsion gently stirred on a magnetic stir plate
overnight, allowing the toluene to evaporate. The SN-38-
loaded micelle solution was ﬁltered through a 0.22μmP E S
ﬁlter, then lyophilized to give a slightly yellow powder.
2.3. High-Performance Liquid Chromatography. The HPLC
instrumentation consisted of a Waters Alliance separation
module (W2695) equipped with a Lichrosphere Select B
(5μm), 250 × 4.6mm column coupled with a Waters multi-
wavelength ﬂuorescence detector (W2475) with excitation
at 355nm and emission at 515nm. Mobile phase consisted
of a 70:30 phosphate buﬀer (10mM NaH2PO4,0 . 1 %T E A ,
pH 3.5)/acetonitrile. Flow rate was isocratic at 0.8mL/min.
Elution time for SN-38 was determined to be 11.6 minutes,
while camptothecin internal standard was 4.2 minutes.Journal of Drug Delivery 3
2.4. Size and Zeta Analysis of IT-141. Particle sizes were
determined using dynamic light scattering on a Wyatt
DynaPro (Santa Barbara, Calif). Micelle solutions were
prepared at 1mg/mL in ﬁltered water and were centrifuged
at 2,000rpm to remove any dust prior to analysis. Zeta
measurements were performed on a Malvern Zetasizer
(Worcestershire, United Kingdom).
2.5. Drugs, Cell Lines, and Animals. SN-38 was purchased
from Yingxuan Pharmaceuticals (Shanghai, China). Camp-
tothecin and irinotecan were purchased from Sigma. All
cells were purchased from American Type Tissue Collection
(ATCC) and maintained in the following media: RPMI 1640
with 10% FBS, 2mM L-Glutamine, and 100 units/mL peni-
cillin/streptomycin (LNCaP, PC-3, MG-63, BxPC-3, MCF-
7, and BT-474), DMEM with 10% FBS, 2mM L-Glutamine
and 100 units/mL penicillin/streptomycin (MDA-MB-453,
MDA-MB-231), F12K with 10% FBS, 2mM L-Glutamine
and 100 units/mL penicillin/streptomycin (A549), and
McCoy’s 5A with 10% FBS, 2mM L-Glutamine, and 100
units/mL penicillin/streptomycin (HT-29 and HCT116). All
media, FBS, and supplements were purchased from Mediat-
ech (Manassas, Va) or Hyclone. Female athymic nude mice
weighing about 20–25g were obtained from Charles River
Laboratories (Wilmington, Mass).
2.6. Cytotoxicity Assay. For assessing cytotoxicity, cancer cell
lines were plated in 96-well white-walled plates. The follow-
ing day, when the cells were 50% conﬂuent, the cells were
treated with IT-141, free SN-38, or irinotecan in complete
growth medium. IT-141 was administered using SN-38-
equivalent concentrations based on the weight loading of
the formulation. The drugs remained on the cells for 72
hours without media change. At this timepoint, cell viability
was determined using the Cell Titer Glo kit and measured
using a luminescent plate reader (BMG Labtech, Cary, NC).
Cells were treated in triplicate. Data are presented as mean ±
standard deviation.
2.7. Pharmacokinetic Studies. HT-29 cells were subcuta-
neously injected into the right ﬂank of nude mice at a
concentration of 5 million in 0.1mL PBS. When the tumors
were approximately 300mm3, mice were randomly divided
into two groups of eight and injected with 30mg/kg (SN-
38-equivalent) of IT-141 or 30mg/kg irinotecan. Injection
occurred by a fast IV bolus into the tail vein in a volume of
0.2mL. The delivery vehicle for IT-141 was isotonic saline
and acidiﬁed (pH 3.5) isotonic saline for irinotecan. Mouse
blood wascollectedat timepoints of5 minutes, 15 minutes, 1
hour,4hours,12hours,24hours,and72hours.Tumorswere
excised at the same timepoints, and snap frozen. plasma was
isolated by centrifugation at 2000rpm for 5 minutes. Plasma
was processed for HPLC analysis by protein precipitation in
ice-cold, acidiﬁed methanol (10% perchloric acid/methanol)
with 100ng/mL camptothecin as internal standard, at a ratio
of 1:4 plasma to methanol. Tumors were homogenized in
20mM ammonium acetate, pH 3.5 and extracted in acidiﬁed
methanol as described above. Samples were vortexed for 10
minutes, centrifuged at 13,000rpm for 10 minutes, and the
supernatant was transferred to HPLC vials for analysis. Data
are presented as mean ± standard deviation.
2.8. Maximum Tolerated Dose (MTD) Studies. HT-29 cells
were subcutaneously injected into the right ﬂank of nude
mice at a concentration of 5 million in 0.1mL PBS. When
the tumors were approximately 300mm3, mice were given
bothsingleandmultidose(Q4D ×3,Day0,4,8)intravenous
injections of IT-141 at doses ranging from 10–90mg/kg.
Body weight was recorded every other day. The MTD was
deﬁned as a dose that caused no greater than a 10% loss in
body weight and no treatment-related deaths.
2.9. Antitumor Eﬃcacy Studies. HT-29 and HCT-116 colon
cancer cells were harvested and resuspended in sterile PBS
at a concentration of 2 million (HT-29) or 4 million (HCT-
116) cells per 0.1mL PBS and injected subcutaneously into
therightﬂankofathymicnudemice.Tumorswereallowedto
establish logarithmic growth (∼7–14 days), and the animals
wererandomlydividedintosixtoeightmicepergroup.Drug
was administered by a fast bolus injection of 0.2mL into the
mouse tail vein on a schedule of Q4D × 3. Bidimensional
tumor measurements were made with calipers once every
other day. Tumor volume was calculated according to the
formula: V = (short diameter)2(long diameter)/2. Percent
inhibition was calculated using the following formula:
100 −
Vgroup −Vgroup 0
VCtl −VCtl 0
×100, (1)
where Vgroup is the tumor volume on the ﬁnal day of the
study, Vgroup 0 is the tumor volume of the group on day 0,
VCtl is the tumor volume of the control group on the ﬁnal
dayofthestudy,andVCtl 0 isthetumorvolumeofthecontrol
group on day 0. Tumor regression was calculated using the
following formula:
Vgroup 0 −Vgroup
100
×100, (2)
where Vgroup is the tumor volume on the ﬁnal day of the
study and Vgroup 0 is the tumor volume of the group on day 0.
Statistical diﬀerences in tumor volume between groups were
calculated using the Student’s t- t e s tu s i n gM i c r o s o f tE x c e l ,
whereby P<0.05 was considered statistically signiﬁcant.
Data are presented as mean tumor volume ± standard error.
3. Results
ITP-101 is a triblock copolymer consisting of poly(ethylene
glycol)-b-poly(aspartic acid)-b-poly(D-leucine-co-tyrosine).
The hydrophobic amino acids provide a core region into
which a hydrophobic drug can reside, and the amphiphilic
PEG block forms a protective corona around the micelle,
giving the delivery system stealth-like properties to avoid
protein opsonization and RES uptake (Figure 1). The use
of both D and L stereoisomers of amino acids in the
leucine/tyrosine core block disrupts the secondary structure4 Journal of Drug Delivery
ITP-101
SN-38
Micelle
formation
IT-141
N3
O
O
O
O
O
O
O O
O
O
270
N
N
N
H
N
H
N
H
N
H
OH
OH
HO
HO
10 20
20
Figure 1: Diagram of the IT-141 formulation. ITP-101 consists of poly(ethylene glycol)-b-poly(aspartic acid)-b-poly(D-leucine-co-
tyrosine), where the hydrophobic amino acids provide a core region into which a hydrophobic drug can reside, and the amphiphilic PEG
block forms a protective corona around the micelle. Addition of SN-38 (shown in red) to ITP-101 (see Section 2) forms an SN-38-loaded
micelle, termed IT-141.
of the polypeptide. Replacing the rodlike helical nature of
the polypeptide with the ﬂexibility of a random coil allows
for signiﬁcant increases in drug loading eﬃciency (data
not shown). The middle aspartic acid block allows for a
hydrogen-bonding segment which can be further stabilized
with the use of metal ions, an aspect that is not utilized for
IT-141.
IT-141 was formulated using ITP-101 with various
concentrations of SN-38, ranging from 1 to 14% (w/w),
achieving greater than 90% loading eﬃciency. Formulations
of IT-141 reconstituted in water or saline resulted in a
homogeneous solution free of precipitate for up to four days
at room temperature, and the lyophilized powder is stable
for months. Following formulation, the aqueous solubility
of SN-38 in IT-141 was 30mg/mL, which is about a 6,000-
fold increase in solubility of SN-38. [25]. Dynamic light
scattering (DLS) experiments demonstrated that the micelle
size was approximately 130nm, with a standard deviation
of ±6nm. Thus, the average size of IT-141 falls within the
desired range to avoid renal clearance (above ∼20nm) and
escape uptake by the RES (below ∼150nm). Zeta potential
measurements from electrophoretic light scattering experi-
ments demonstrated that the surface charge of the micelle
is overall neutral, with a range of readings from −5t o5m V .
T h es e n s i t i v i t yo fv a r i o u sc a n c e rc e l ll i n e st of r e eS N -
38, IT-141, and irinotecan was compared in a cytotoxicity
assay. As shown in Table 1, both free SN-38 and IT-141 were
extremely potent, and the sensitivity of the cells to IT-141
was similar to free SN-38 across the cell lines. Irinotecan was
several orders of magnitude less toxic than either free SN-38
or IT-141. Certain cell lines (PC-3, MDA-MB-231, and BT-
474) were insensitive to both free SN-38 and IT-141.
To determine the MTD of IT-141, HT-29 tumor-bearing
nude mice were given both single and multidose (Q4D × 3)
intravenousinjectionsofIT-141.Thesestudiesdemonstrated
that the multidose MTD of IT-141 in tumor-bearing animals
was 45mg/kg and single dose MTD was 60mg/kg. Using
30mg/kg of IT-141 as a safe dose, the pharmacokinetic (PK)
proﬁle and tumor accumulation of SN-38 delivered from
IT-141 then compared to irinotecan in nude mice bearing
HT-29 tumors (Table 2). Mice receiving a single injection
of 30mg/kg IT-141 achieved a signiﬁcant improvement in
SN-38 plasma concentration and exposure compared to
30mg/kg of irinotecan (Figure 2(a), Table 2). The Cmax for
both groups was achieved by the ﬁrst measured time point
of 5 minutes, with >200-fold higher SN-38 concentration
in mice treated with IT-141 (209μg/mL) compared to
irinotecan (1.0μg/mL). SN-38 exposure as measured by
area under curve (AUC) from irinotecan was 2.5μg∗hr/mL,
while SN-38 exposure from IT-141 was 13.8-fold greater at
34.6μg∗hr/mL. No data could be obtained for irinotecan
plasma concentrations beyond 12 hours as the concentration
fell below the limit of detection. The concentration of SN-38
in the tumor over time is plotted in Figure 2(b). The tumor
AUC of IT-141 was determined to be 16.4μg∗h/g, which
wassigniﬁcantlyhigherthanirinotecanat1.9μg∗h/g.IT-141
also had a 47-fold higher Cmax in the tumor than irinotecan
(9.4μg/mL versus 0.2μg/mL).
Based on the pharmacokinetic data, it was hypothesized
that IT-141 would show superior antitumor eﬃcacy inJournal of Drug Delivery 5
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Figure 2: Plasma and tumor pharmacokinetics of IT-141 compared to irinotecan. (a) HT-29 tumor-bearing nude mice (eight mice per
group) were administered a single bolus intravenous injection of IT-141 or irinotecan at a dose of 30mg/kg. (a) Plasma concentration of
SN-38 compared to irinotecan plotted versus time. Inset: plasma concentrations plotted from 5min to 1 hour. (b) Tumor concentration of
SN-38 compared to irinotecan plotted versus time. Values are presented as mean ± standard deviation.
Table 1: IC50 values (μM) of IT-141 compared to free SN-38 and irinotecan in cancer cell lines. Data are presented as mean ± standard
deviation.
Cell line IT-141 (μM) Free SN-38 (μM) Irinotecan (μM)
Colon HT-29 0.0374 ±.001 0.0452 ±.002 24.6 ±6.4
HCT-116 0.165 ±.021 0.133 ±.037 16.3 ±1.3
Prostate PC-3 >5.0 >5.0 >100
LNCaP 0.081 ±0.006 0.083 ±0.008 10.7 ±2.2
Osteosarcoma MG-63 0.080 ±0.004 0.076 ±0.002 7.2 ±0.9
Pancreatic BxPC-3 0.072 ±0.004 0.072 ±0.002 6.5 ±1.3
Breast
MDA-MB-453 0.679 ±0.006 0.661 ±0.038 >100
MDA-MB-231 >1.0 >1.0 66.3 ±6.0
MCF-7 0.717 ±0.141 0.529 ±0.017 86.0 ±4.6
BT-474 >3.0 >3.0 >200
Lung A549 0.091 ±0.002 0.099 ±0.001 7.7 ±1.0
Table 2: Plasma and tumor pharmacokinetics of IT-141 compared
to irinotecan. Plasma AUC = μg∗h/mL, tumor AUC = μg∗h/g.
Drug AUC Half-life (h) Cmax (μg/mL)
IT-141 (plasma) 34.6 8.5 209.5
Irinotecan (plasma) 2.5 1.6 1.0
IT-141 (tumor) 16.4 3.9 9.4
Irinotecan (tumor) 1.9 17.5 0.2
colon cancer xenograft models compared to irinotecan. To
test the antitumor eﬃcacy of IT-141, HT-29 tumor-bearing
mice were treated with either ITP-101 alone at 300mg/kg,
irinotecan at 60mg/kg, or IT-141 at 30mg/kg (Figure 3(a)).
Treatment with irinotecan at 60mg/kg, which is near its
MTD on this dosing schedule, did not inhibit HT-29 tumor
growth signiﬁcantly compared to polymer alone [26, 32].
However,treatmentwithIT-141athalfthedoseofirinotecan
induced signiﬁcant tumor regression by day 18, ultimately
resulting in complete inhibition of tumor growth compared
to ITP-101 control and 35% regression from initial tumor
volume (P = 0.002). Dose-ranging studies were then per-
formed to determine if the antitumor eﬃcacy of IT-141 is
dose dependent (Figure 3(b)). HT-29 tumor-bearing mice
were intravenously administered IT-141 at doses of 1, 5, 10,
15, 30, and 45mg/kg via tail vein injection. Treatment with
1, 5, or 10mg/kg did not result in a statistically signiﬁcant
inhibitionoftumorgrowthcomparedtocontrolmicereceiv-
ing only saline. By day 20, treatment with 15mg/kg IT-141
resulted in a 54% inhibition of tumor growth, respectively,
compared to mice treated with saline (P = 0.028). Treatment
with 30 and 45mg/kg resulted in complete tumor growth
inhibition compared to saline control, with tumor regression
of 59 and 87%, respectively (P = 0.005 for both).
Similar results were found using another colon cancer
xenograft model, HCT116 (Figure 3(c)). In this model, a6 Journal of Drug Delivery
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Figure 3: Antitumor eﬃcacy of IT-141 in colorectal cancer xenograft models. (a) HT-29 tumor-bearing mice (eight mice per group) were
injected intravenously with ITP-101 alone (300mg/kg), IT-141 (30mg/kg), or irinotecan (60mg/kg) on a Q4D × 3s c h e d u l e .( b )H T - 2 9
tumor-bearing mice (seven mice per group) were injected with 1, 5, 10, 15, 30, or 45mg/kg of IT-141 along with a saline control group. (c)
HCT-116 tumor-bearing mice (six mice per group) were injected with 5, 15, or 30mg/kg of IT-141 along with saline and ITP-101 control.
Asterisks denote that treatment group is statistically diﬀerent from control group (P<0.05). Arrows indicate days of injection (days 0, 4,
and 8). Data are presented as mean tumor volume ± standard error.
dose of 5mg/kg resulted in a 59% inhibition of tumor
growth (P = 0.008) compared to the ITP-101-treated group.
Treatment with IT-141 at 15 and 30mg/kg in this model
resulted in complete inhibition of tumor growth compared
to the ITP-101 polymer control, with 15% and 51% regres-
sion, respectively (P = 1.0e−4 and 8.1
−5). Taken together,
these data demonstrate that IT-141 achieved signiﬁcantly
greater antitumor eﬃcacy, compared to irinotecan, and
dose-dependent tumor regression in two colorectal cancer
xenograft models of colon cancer, with eﬀective doses be-
tween 15 and 30mg/kg.
A ﬁnal study was performed whereby IT-141 formula-
tions with diﬀerent weight loadings of SN-38 were compared
to each other. IT-141 formulations were prepared with
11% (IT-141-11%) and 4% (IT-141-4%) SN-38 (w/w),
and equivalent doses of SN-38 were administered i.v. in
an HT-29 colon cancer xenograft model (Figure 4). There
were no statistical diﬀerences in eﬃcacy between the two
formulations at either 30mg/kg (P = 0.292), 15mg/kg (P =
0.119), or 5mg/kg (P = 0.138). These data demonstrate that
thepercentloadingbyweightofSN-38intothemicellesdoes
not aﬀect antitumor activity.Journal of Drug Delivery 7
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Figure 4: Antitumor eﬃcacy of diﬀerent weight loadings of IT-141
in an HT-29 xenograft model. IT-141 was formulated to contain
either 4 or 11% SN-38 by weight and was administered i.v. to nude
mice bearing HT-29 tumors at 5, 15, or 30mg/kg. Each group
contained six mice. Arrows indicate days of injection (days 0, 4, and
8). Data are presented as mean tumor volume ± standard error.
4. Discussion
In this report, a novel triblock copolymer was used to encap-
sulate and solubilize the hydrophobic drug, SN-38, which
is the active metabolite of irinotecan. Although irinotecan
is used in the clinic as a prodrug, its eﬃcacy is reliant
upon carboxylesterase enzymes localized in the liver and
gastrointestinal tract for conversion to the active metabolite,
SN-38. Irinotecan treatment is often followed by late-stage
diarrhea with 24% grade 4 incidence and can require antid-
iarrheal premedication [33]. This limits the dose of irinote-
can that can be administered safely in subsequent admin-
istrations, thereby reducing response rates in these patients
[34, 35]. SN-38 is a potent cytotoxic compound that, by
itself, cannot be used in the clinic due to its extreme hydro-
phobicity. Hamaguchi et al. have eﬀectively addressed the
solubility problem of SN-38 by conjugating SN-38 to PEG-
poly(glutamic acid), forming a micelle called NK012, which
is currently in clinical trials [27]. Other nanocarriers for SN-
38 have been developed involving conjugation of SN-38 to
ap o l y m e ro rp e p t i d e[ 24, 25]. As an alternative approach
to direct SN-38 conjugation, a novel triblock copolymer was
usedtoencapsulateSN-38intoapolymermicelle,precluding
the need to modify the drug and for cleavage of the bond to
release the active drug. The ITP-101 triblock copolymer was
developed to eﬃciently encapsulate hydrophobic molecules
and release them at the site of disease (in the tumor) without
drug conjugation.
Encapsulation of SN-38 to create IT-141 resulted in a
6,000-foldincreaseinsolubilityofSN-38andamicellesizeof
130nm, which is ideal for accumulation in tumors due to the
EPR eﬀect [36]. In vitro, IT-141 was found to possess potent
cytotoxic activity, which was similar to that of free SN-38
but several fold more potent than irinotecan. Cell lines that
were resistant to killing by IT-141 were also resistant to free
SN-38, which may indicate a natural insensitivity of these
cell lines to inhibition of topoisomerase I. This could arise
through alterations in the expression of, or mutations in, the
gene encoding topoisomerase I or the activity of drug eﬄux
pumps [37]. It has been shown that the drug eﬄux pump
ABCG2 is overexpressed in cells resistant to SN-38 [38].
The pharmacokinetic proﬁle of IT-141 demonstrated
signiﬁcant improvement in exposure and CMax for SN-38,
with a modest improvement in half-life, compared to SN-
38 derived from irinotecan. Importantly, the plasma AUC
from IT-141 exposure was 14-fold higher than the SN-38
exposure from irinotecan administered at the same dose
(34.6μg∗hr/mL versus 2.5μg∗hr/mL). Similarly, IT-141
demonstrated higher exposure in HT-29 tumors, as mea-
sured by AUC, than irinotecan. The higher AUC of IT-141
in the tumor indicated that it would potentially be more
eﬃcacious than irinotecan in xenograft models. Indeed, IT-
141 was found to be superior to irinotecan in an HT-29
xenograft model and was potent in dose-range ﬁnding stud-
ies in both HT-29 and HCT-116 xenografts. In both models,
tumor regression was observed at 30mg/kg in the HT-29
model and 15mg/kg in the HCT116 model.
During the development of IT-141, it was found that IT-
141 could be formulated with SN-38 with weight loadings
in the range of 1–14%. Diﬀerent IT-141 formulations were
prepared with varying weight loadings of SN-38 and were
evaluated in an HT-29 xenograft experiment. It was found
that IT-141-4%w/w had equivalent antitumor activity to
IT-141-11%w/w, demonstrating no diﬀerences in eﬃcacy
between these formulations. It can be speculated, therefore,
that despite SN-38 loading diﬀerences between the micelle,
equivalent or similar overall concentrations of SN-38 are
being delivered to these tumors.
In summary, IT-141 is a novel SN-38-loaded polymer
micellewithsuperiorpharmacokineticsandantitumoractiv-
ity compared to irinotecan. Although irinotecan is eﬀective
in the clinic, the ability to deliver SN-38 could be a superior
treatment option for many patients. These data suggest that
IT-141 may show activity in patients with solid tumors.
5. Conclusions
IT-141 is a micelle containing encapsulated SN-38 that
was designed for systemic delivery. IT-141 increased the
solubility of SN-38 by ∼6,000-fold and had a diameter of
130nm. IT-141 demonstrated superior pharmacokinetics to
irinotecanandpotentantitumoractivityinHT-29andHCT-
116 colorectal cancer xenograft models. In summary, IT-141
is a promising new therapeutic agent for colorectal cancer
that warrants clinical investigation.
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